The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
beta Blockade after myocardial infarction: systematic review and meta regression analysis
Open accessAbstract
OBJECTIVES: To assess the effectiveness of beta blockers in short term treatment for acute myocardial infarction and in longer term secondary prevention; to examine predictive factors that may influence outcome and therefore choice of drug; and to examine the clinical importance of the results in the light of current treatment. DESIGN: Systematic review of randomised controlled trials. SETTING: Randomised controlled trials. SUBJECTS: Patients with acute or past myocardial infarction. INTERVENTION: beta Blockers compared with control. MAIN OUTCOME MEASURES: All cause mortality and non-fatal reinfarction. RESULTS: Overall, 5477 of 54 234 patients (10.1%) randomised to beta blockers or control died. We identified a 23% reduction in the odds of death in long term trials (95% confidence interval 15% to 31%), but only a 4% reduction in the odds of death in short term trials (-8% to 15%). Meta regression in long term trials did not identify a significant reduction in effectiveness in drugs with cardioselectivity but did identify a near significant trend towards decreased benefit in drugs with intrinsic sympathomimetic activity. Most evidence is available for propranolol, timolol, and metoprolol. In long term trials, the number needed to treat for 2 years to avoid a death is 42, which compares favourably with other treatments for patients with acute or past myocardial infarction. CONCLUSIONS: beta Blockers are effective in long term secondary prevention after myocardial infarction, but they are underused in such cases and lead to avoidable mortality and morbidity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In those post-myocardial infarction and in heart failure patients, use of beta-blockade in carefully titrated doses is associated with improved outcomes.62,63”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [62]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Sleight, R. B., Sleight, P., Parish, S., Appleby, P. N., Collins, R., & Baigent, C. (1988) · PubMed · Cited by 2,868
The TIMI Study Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198903093201002 · Cited by 1,024
Gottlieb, S. S., McCarter, R., & Vogel, R. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808203390801 · Cited by 966
The Effect of Diltiazem on Mortality and Reinfarction after Myocardial Infarction
The Multicenter Diltiazem Postinfarction Trial Research Group (1988) · New England Journal of Medicine · doi:10.1056/nejm198808183190701 · Cited by 828
The Effect of Warfarin on Mortality and Reinfarction after Myocardial Infarction
Smith, P., Arnesen, H., & Holme, I. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007193230302 · Cited by 637
Bayesian approaches to random-effects meta-analysis: a comparative study
Smith, T. C., Spiegelhalter, D. J., & Thomas, A. (1995) · Statistics in Medicine · doi:10.1002/sim.4780142408 · Cited by 568
Lemon, D. (1987) · Journal of Emergency Medicine · doi:10.1016/0736-4679(87)90192-2 · Cited by 562
A LIKELIHOOD APPROACH TO META-ANALYSIS WITH RANDOM EFFECTS
Hardy, R., & Thompson, S. G. (1996) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19960330)15:6 · Cited by 522
The effect of diltiazem on mortality and reinfarction after myocardial infarction
Warnock, E. W. (1989) · Journal of Emergency Medicine · doi:10.1016/0736-4679(89)90390-9 · Cited by 512
Robins, J. M., Breslow, N. E., & Greenland, S. (1986) · Biometrics · doi:10.2307/2531052 · Cited by 476
REDUCTION OF SUDDEN DEATHS AFTER MYOCARDIAL INFARCTION BY TREATMENT WITH ALPRENOLOL
Wilhelmsson, C., Wilhelmsen, L., Vedin, J. A., Tibblin, G., & Werkö, L. (1974) · The Lancet · doi:10.1016/s0140-6736(74)90807-1 · Cited by 459
Fleiss, J. L., & Gross, A. J. (1991) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(91)90261-7 · Cited by 401
Heidenreich, P. A., Lee, T. T., & Massie, B. M. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(97)00104-6 · Cited by 357
Doughty, R. N., Rodgers, A., Sharpe, N., & MacMahon, S. W. (1997) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a015297 · Cited by 228
Meta‐analysis for 2 × 2 tables: A bayesian approach
Carlin, J. B. (1992) · Statistics in Medicine · doi:10.1002/sim.4780110202 · Cited by 164
The assessment of beta‐adrenoceptor blocking drugs in man.
McDevitt, D. (1977) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1977.tb00756.x · Cited by 129
The evidence for beta blockers in heart failure
Cleland, J. G. F., McGowan, J., Clark, A. L., & Freemantle, N. (1999) · BMJ · doi:10.1136/bmj.318.7187.824 · Cited by 107
Self-citationEarly or Deferred Zidovudine Therapy in HIV-Infected Patients without an AIDS-Defining Illness
Ioannidis, J. P. A., Cappelleri, J. C., Lau, J., Skolnik, P. R., Melville, B., Chalmers, T. C., & Sacks, H. S. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-11-199506010-00009 · Cited by 92
Crowcroft, N. S., Infuso, A., Ilèf, D., Guenno, B. L., Jc, D., Loock, F. V., & Clement, J. P. G. (1999) · BMJ · doi:10.1136/bmj.318.7200.1737 · Cited by 61
Use of secondary prophylaxis against myocardial infarction in the north of England.
Eccles, M., & Bradshaw, C. (1991) · BMJ · doi:10.1136/bmj.302.6768.91 · Cited by 60
Viskin, S., & Barron, H. V. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(96)00428-6 · Cited by 49
Freemantle, N., Mason, J. M., & Eccles, M. (1999) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462399015238 · Cited by 28
Self-citationNew Drugs. Beta-blockers and sympathomimetics.
Feely, J., de Vane, P. J., & Maclean, D. (1983) · BMJ · doi:10.1136/bmj.286.6370.1043 · Cited by 25
Increasing prescription of drugs for secondary prevention after myocardial infarction
Smith, J., & Channer, K. S. (1995) · BMJ · doi:10.1136/bmj.311.7010.917 · Cited by 22
Intravenous β blockade in acute myocardial infarction
Owen, A. (1998) · BMJ · doi:10.1136/bmj.317.7153.226 · Cited by 18
A drink (or less) a day is not all good news
Wunsch, H. (1997) · The Lancet · doi:10.1016/s0140-6736(05)63954-2 · Cited by 3
Research works printed but not linked: 3
- Viskin S, Barron HV. -Blockers prevent cardiac death following myocar- dial infarction: so why are so many infarct survivors discharge without -blockers? Am J Cardiol 1996;78:821-2.
- Spiegelhalter D, Thomas A, Best N, Gilks W. BUGS: Bayesian inference using Gibbs sampling, Version 0.50. Cambridge: Medical Research Council Biostatistics Unit, 1995.
- Feely J, de Vane PJ, Maclean D. -Blockers and sympathomimetics. BMJ 1983;286:1043-7.
Cited by
Sorted by citations
2013 ESH/ESC Guidelines for the management of arterial hypertension
Authors Task Force Members, Mancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Böhm, M., Christiaens, T., Cífková, R., Backer, G. D., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,739
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000065 · Cited by 7,391
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes
Knuuti, J., Wijns, W., Saraste, A., Capodanno, D., Barbato, E., Funck-Brentano, C., Prescott, E., Storey, R. F., Deaton, C., Cuisset, T., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz425 · Cited by 7,166
Metadata
- Authors
- Freemantle, N., Cleland, J., Young, P., Mason, J., & Harrison, J.
- Affiliations
- University of York (GB)
- University of Hull (GB)
- Corresponding author
- Freemantle, N.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 1999-06-26
- Volume
- 318
- Issue
- 7200
- Pages
- 1730-1737
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- PMC
- PMC31101
- OpenAlex
- W2070568974
- Cited by
- 1,509
- References
- 34
- Citations by year
- 2026: 27 · 2025: 43 · 2024: 38 · 2023: 30 · 2022: 42 · 2021: 36 · 2020: 49 · 2019: 47 · 2018: 53 · 2017: 57 · 2016: 58 · 2015: 48 · 2014: 67 · 2013: 74 · 2012: 83
- FWCI
- 7.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- BMJ (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Health and Mental Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Ischemia and Reperfusion
- Keywords
- beta-blockers, myocardial infarction, secondary prevention, all-cause mortality, reinfarction, cardioselectivity, intrinsic sympathomimetic activity, propranolol, timolol, metoprolol, number needed to treat, predictors of treatment response
- MeSH terms
- Adrenergic beta-Antagonists, Humans, Myocardial Infarction, Regression Analysis, Randomized Controlled Trials as Topic, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
